现代生物医学进展2024,Vol.24Issue(20) :3984-3986.DOI:10.13241/j.cnki.pmb.2024.20.051

参麦注射液联合吉西他滨和顺铂对晚期NSCLC患者肿瘤标志物、T淋巴细胞亚群和血清凋亡分子的影响

Effects of Shenmai Injection Combined with Gemcitabine and Cisplatin on Tumor Markers,T Lymphocyte Subsets and Serum Apoptotic Molecules in Patients with Advanced NSCLC

陈慧昱 柯丽 王赟 刘鑫佳 杨光
现代生物医学进展2024,Vol.24Issue(20) :3984-3986.DOI:10.13241/j.cnki.pmb.2024.20.051

参麦注射液联合吉西他滨和顺铂对晚期NSCLC患者肿瘤标志物、T淋巴细胞亚群和血清凋亡分子的影响

Effects of Shenmai Injection Combined with Gemcitabine and Cisplatin on Tumor Markers,T Lymphocyte Subsets and Serum Apoptotic Molecules in Patients with Advanced NSCLC

陈慧昱 1柯丽 2王赟 2刘鑫佳 2杨光2
扫码查看

作者信息

  • 1. 空军军医大学第一附属医院检验科 陕西西安 710032
  • 2. 空军军医大学第二附属医院肿瘤科 陕西西安 710038
  • 折叠

摘要

目的:探讨参麦注射液联合吉西他滨和顺铂对晚期非小细胞肺癌(NSCLC)患者肿瘤标志物、T淋巴细胞亚群和血清凋亡分子的影响.方法:将在2020年3月~2022年12月期间我院收治的118例晚期NSCLC患者以随机数字表法分为联合组(n=59,参麦注射液联合吉西他滨和顺铂治疗)和对照组(n=59,吉西他滨和顺铂治疗).对比两组肿瘤标志物水平、T淋巴细胞亚群、凋亡分子.结果:与对照组相比,联合组治疗后细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、鳞状细胞癌相关抗原(SCC)、糖类抗原 125(CA125)、B 淋巴细胞瘤(Bcl-2)、生存素(Survivin)、CD8+更低,Bcl-2 相关 X 蛋白(Bax)、CD3+、CD4+、CD4+/CD8+更高(P<0.05).结论:参麦注射液联合吉西他滨和顺铂治疗晚期NSCLC患者,能够降低肿瘤标志物水平,减轻患者免疫抑制,调节血清凋亡分子水平.

Abstract

Objective:To investigate the effects of shenmai injection combined with gemcitabine and cisplatin on tumor markers,T lymphocyte subsets and serum apoptotic molecules in patients with advanced non-small cell lung cancer(NSCLC).Methods:118 patients with advanced NSCLC who were admitted to our hospital from March 2020 to December 2022 were divided into combined group(n=59,treated with shenmai injection combined with gemcitabine and cisplatin)and control group(n=59,treated with gemcitabine and cisplatin)by random number table method.The tumor marker level,T lymphocyte subsets and apoptotic molecules were compared between two groups.Results:Compared with control group,cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA),sqamous cell carcinoma antigen(SCC),carbohydrate antigen 125(CA125),B-cell lymphoma(Bcl-2),Survivin(Survivin),CD8+were lower in combined group after treatment,and Bcl-2-related X protein(Bax)and CD3+,CD4+,CD4+/CD8+were higher(P<0.05).Conclusion:Shenmai injection combined with gemcitabine and cisplatin for the treatment of advanced NSCLC Patients,which can reduce tumor markers level,reduce the immunosuppression of patients,regulate serum apoptotic molecules level.

关键词

参麦注射液/吉西他滨/顺铂/晚期非小细胞肺癌/肿瘤标志物/T淋巴细胞亚群/凋亡分子

Key words

Shenmai Injection/Gemcitabine/Cisplatin/Advanced non-small cell lung cancer/Tumor markers/T lymphocyte subsets/Apoptotic molecules

引用本文复制引用

出版年

2024
现代生物医学进展
黑龙江省森工总医院 哈尔滨医科大学附属第四医院

现代生物医学进展

CSTPCD
影响因子:0.755
ISSN:1673-6273
段落导航相关论文